

## Molecular and Biochemical Heterogeneity of Class B Carbapenem-Hydrolyzing $\beta$ -Lactamases in *Chryseobacterium meningosepticum*

SAMUEL BELLAI, DANIEL AUBERT, THIERRY NAAS, AND PATRICE NORDMANN\*

*Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, 94275 Le Kremlin-Bicêtre Cedex, France*

Received 4 October 1999/Returned for modification 14 February 2000/Accepted 21 April 2000

Although the carbapenem-hydrolyzing  $\beta$ -lactamase (CH $\beta$ L) BlaB-1 is known to be in *Chryseobacterium meningosepticum* NCTC 10585, a second CH $\beta$ L gene, *bla*<sub>GOB-1</sub>, was cloned from another *C. meningosepticum* clinical isolate (PINT). The G+C content of *bla*<sub>GOB-1</sub> (36%) indicated the likely chromosomal origin of this gene. Its expression in *Escherichia coli* DH10B yields a mature CH $\beta$ L with a pI of 8.7 and a relative molecular mass of 28.2 kDa. In *E. coli*, GOB-1 conferred resistance to narrow-spectrum cephalosporins and reduced susceptibility to ureidopenicillins, broad-spectrum cephalosporins, and carbapenems. GOB-1 had a broad-spectrum hydrolysis profile including penicillins and cephalosporins (but not aztreonam). The catalytic efficiency for meropenem was higher than for imipenem. GOB-1 had low amino acid identity with the class B CH $\beta$ Ls, sharing 18% with the closest, L-1 from *Stenotrophomonas maltophilia*, and only 11% with BlaB-1. Most of the conserved amino acids that may be involved in the active site of CH $\beta$ Ls (His-101, Asp-103, His-162, and His-225) were identified in GOB-1. Sequence heterogeneity was found for GOB-1-like and BlaB-1-like  $\beta$ -lactamases, having 90 to 100% and 86 to 100% amino acid identity, respectively, among 10 unrelated *C. meningosepticum* isolates. Each isolate had a GOB-1-like and a BlaB-1-like gene. The same combination of GOB-1-like and BlaB-1-like  $\beta$ -lactamases was not found in two different isolates. *C. meningosepticum* is a bacterial species with two types of unrelated chromosome-borne class B CH $\beta$ Ls that can be expressed in *E. coli* and, thus, may represent a clinical threat if spread in gram-negative aerobes.

*Chryseobacterium meningosepticum* is the most clinically important human pathogen among the *Chryseobacterium* and *Flavobacterium* genera. It is responsible for neonatal meningitis, with a mortality of up to 50% (17). *C. meningosepticum* is also found in pneumonia (J. Fujita, Y. Hata, and S. Irino, Letter, Lancet 335:544, 1990) and endocarditis (7, 52) in immunocompromised patients.

*C. meningosepticum* (formerly known as *Flavobacterium meningosepticum*) belonged to the *Flavobacterium* genus until 1994. Since then, it has been reclassified and belongs now to the *Chryseobacterium* genus, like *Chryseobacterium indologenes* and *Chryseobacterium gleum* (56).

*C. meningosepticum* is naturally resistant to most  $\beta$ -lactams, including carbapenems (16). A carbapenem-hydrolyzing  $\beta$ -lactamase, (CH $\beta$ L) BlaB (BlaB-1), from *C. meningosepticum* NCTC 10585 (CIP 6058) has been described (46). This enzyme belongs to the Ambler class B metallo- $\beta$ -lactamase group (2), with a broad substrate profile, a relative molecular mass of 26 kDa, and a pI value of 8.5 (46). Recently, in the same species, Ambler class A extended-spectrum  $\beta$ -lactamases have also been characterized (6, 45). These extended-spectrum  $\beta$ -lactamases are inhibited by clavulanic acid, ceftiofloxacin, moxalactam, and imipenem, and their substrate profile does not include carbapenems.

Metalloenzymes usually have a broad spectrum of hydrolysis, except for CphA-1 from *Aeromonas hydrophila* (31, 49), and are resistant to clinically available  $\beta$ -lactamase inhibitors (8). Within the last few years, metallo- $\beta$ -lactamases IMP-1,

VIM-1, and VIM-2 have been identified as chromosome, plasmid, and/or integron located in several pathogens, such as *Acinetobacter baumannii* (14), *Alcaligenes xylosoxydans*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Serratia marcescens* (3, 21, 22, 26, 30, 36, 42). IMP-1 is widespread in Japan (50, 51). The origin of these CH $\beta$ Ls remains, however, unknown.

Our preliminary experiment using isoelectric focusing (IEF) electrophoresis revealed a heterogeneity of pI values in *C. meningosepticum* isolates. Thus, characterization of the  $\beta$ -lactamase content of *C. meningosepticum* initiated with the class A ESBLs was continued (6). We report the molecular and biochemical characterization of the CH $\beta$ L GOB-1 that was weakly related to any class B CH $\beta$ Ls, including BlaB-1. Additionally, sequence analysis of the CH $\beta$ L genes of 10 *C. meningosepticum* isolates revealed that each isolate possessed a combination of both types of CH $\beta$ Ls. A combination of two naturally occurring CH $\beta$ L genes in the same bacterial species had not been reported previously.

### MATERIALS AND METHODS

**Bacterial strains.** *C. meningosepticum* PINT was isolated at the Raymond Poincaré hospital (Garches, France). *C. meningosepticum* AMA and GEO were isolated at the Bicêtre hospital (Le Kremlin-Bicêtre, France), both from tracheoalveolar aspirations. *C. meningosepticum* AB1572 and H01J100 were from Brita Bruun (11), and reference strains *C. meningosepticum* CIP 6057 (NCTC 10016), CIP 6058 (NCTC 10585), CIP 6059 (NCTC 10586), CIP 7830 (NCTC 11305), and CIP 79.5 (NCTC 11306) were from the Pasteur Institute (Paris, France). The *C. meningosepticum* isolates and reference strains were epidemiologically unrelated (data not shown).

*Escherichia coli* DH10B and rifampin-resistant *E. coli* JM109 were used for cloning and conjugation assays, respectively, and have been described previously (40, 41). *C. meningosepticum* isolates were identified as previously described (6, 39, 56). All strains were stored at  $-70^{\circ}\text{C}$  in Trypticase soy (TS) broth supplemented with 15% glycerol until testing.

\* Corresponding author. Mailing address: Service de Bactériologie-Virologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France. Phone: 33 1 45 21 36 32. Fax: 33 1 45 21 63 40. E-mail: nordmann.patrice@bct.ap-hop-paris.fr.

TABLE 1. Plasmids used in this study

Plasmid	Relevant genotype or phenotype	Source or reference
pBK-CMV phagemid	Neomycin and kanamycin resistant	Stratagene
pPCRScript Cam SK	Chloramphenicol resistant	Stratagene
pBS2	A 2.4-kb DNA fragment from <i>C. meningosepticum</i> PINT that contained <i>bla</i> <sub>GOB-1</sub> in the <i>Bam</i> HI site of pBK-CMV	This study
pBS3	Entire <i>bla</i> <sub>GOB-1</sub> gene in the <i>Srf</i> I site of pPCRScript Cam SK	This study
pBS4	Entire <i>bla</i> <sub>BlaB-1</sub> gene in the <i>Srf</i> I site of pPCRScript Cam SK	This study

**Antimicrobial agents and MIC determinations.** The antimicrobial agents used in this study have been described (41). MICs were determined by an agar dilution technique on Mueller-Hinton agar (Sanofi-Diagnostics Pasteur) with an inoculum of  $10^4$  CFU per spot (34). The plates were incubated at 35°C for 18 h before MIC determinations were performed as previously described (34).

**Cloning experiments, PCR amplifications, and recombinant plasmids.** Genomic DNAs were extracted as described previously (35). Fragments from *Sau*3AI partially digested genomic DNA from *C. meningosepticum* PINT were cloned in pBK-CMV phagemid (Stratagene, Ozyme, Amsterdam, The Netherlands) (Table 1) and expressed in *E. coli* DH10B as previously described (35). Antibiotic-resistant colonies were selected onto amoxicillin (30  $\mu$ g/ml) and kanamycin (30  $\mu$ g/ml) containing TS agar plates.

Recombinant plasmid DNA was obtained from 100-ml TS broth cultures grown overnight in the presence of amoxicillin (30  $\mu$ g/ml) at 37°C. Plasmid DNAs were recovered by using Qiagen columns (Qiagen, Courtaboeuf, France) before restriction digest analyses.

16S rDNA fragments were amplified by PCR using the universal 16S RNA primers 5'-AGAGTTTGATCCTGGYTYAGA-3' and 5'-ACGGYTACCTGTACGACTTC-3', where Y is C or T and H is A, C, or T (4), and genomic DNAs of *C. meningosepticum* isolates as the template. Primers used to amplify *bla*<sub>GOB-1</sub>-like genes were primer 1 (5'-GCTATGAGAAATTTGCTACACTG-3') or primer 3 (5'-GGAGTGGTAAAGATGAAATGTGC-3') and primer 2 (5'-TCATACTATTATCTGGG-3') (Fig. 1).

In order to establish a comparison of MICs of  $\beta$ -lactams for *E. coli* DH10B harboring either *bla*<sub>GOB-1</sub> or *bla*<sub>BlaB-1</sub>, PCR products of *bla*<sub>GOB-1</sub> from *C. meningosepticum* PINT were obtained using primers 2 and 3, and those for *bla*<sub>BlaB-1</sub> from *C. meningosepticum* CIP 6058 were obtained using primers 4 (5'-GTGAA TGTAGCAGAGTGTAAATG-3') and primer 5 (5'-GTTGCTCGTTAAGCG TTCC-3') located at the 5' and the 3' end of *bla*<sub>BlaB-1</sub> (Table 1) (46). Each PCR fragment was cloned into the same pPCR-Script CamSK vector (Stratagene) and electrotransformed into *E. coli* DH10B.

**Conjugation assays, plasmid content, and Southern hybridization.** Plasmid DNA extractions of *C. meningosepticum* isolates were attempted according to two different methods (18, 24). Direct transfer of resistance genes into in vitro-obtained rifampin-resistant *E. coli* JM109 was attempted by liquid and solid conjugation assays and by electroporation of the putative plasmid DNA suspension into *E. coli* DH10B (41). Transconjugants and electroporants were selected on TS agar plates containing either rifampin (200  $\mu$ g/ml) and amoxicillin (30  $\mu$ g/ml) or amoxicillin, respectively. Southern hybridizations were performed using a 0.8% electrophoresis gel containing unrestricted genomic DNAs of *C. meningosepticum* isolates and a PCR-prepared internal probe for *bla*<sub>GOB-1</sub> (see below). Visualization was made using the ECL nonradioactive hybridization kit as described by the manufacturer (Amersham Pharmacia Biotech, Orsay, France).

**DNA sequencing and protein analysis.** Sequencing of the 2.4-kb cloned DNA fragment of recombinant plasmid pBS2, of 16S rDNA fragments, and of PCR products that contained *bla*<sub>BlaB-1</sub>-like and *bla*<sub>GOB-1</sub>-like genes was performed using an ABI 373 sequencer (Applied Biosystems, Foster City, Calif.). The nucleotide and deduced protein sequences were analyzed with software available over the Internet at the National Center for Biotechnology Information website (<http://www.ncbi.nlm.nih.gov>) and at Pedro's BioMolecular Research Tools website ([http://www.fmi.ch/biology/research\\_tools.html](http://www.fmi.ch/biology/research_tools.html)), and hydrophobicity analysis of the N-terminal region of the open reading frame (ORF) was performed as described (<http://genome.cbs.dtu.dk/services/SignalP/> [25]). Multiple nucleotide or protein sequence alignments were carried out using the program ClustalW (<http://www2.ebi.ac.uk/clustalw>). A dendrogram of GOB-1  $\beta$ -lactamase was derived from the multiple sequence alignment by a parsimony method using the phylogeny package PAUP (Phylogenetic Analysis Using Parsimony) version 3.0 (53).

**$\beta$ -Lactamase extraction.** A culture of *E. coli* DH10B (pBS2) was grown overnight at 37°C in 4 liters of TS broth containing kanamycin (30  $\mu$ g/ml) and amoxicillin (30  $\mu$ g/ml). Bacterial suspensions were pelleted, resuspended in 40 ml of 20 mM Tris-HCl buffer (pH 8), disrupted by sonification (three times at 50 W for 30 s using a Vibra Cell 75022 Phospholyser [Bioblock, Illkirch, France]), and centrifuged for 1 h at 48,000  $\times$  g at 4°C. Nucleic acids were precipitated by addition of 0.2 M spermine (7% [vol/vol]) (Sigma, Saint-Quentin Fallavier, France) overnight at 4°C. This suspension was ultracentrifuged at 100,000  $\times$  g for 1 h at 4°C, and the supernatant contained the  $\beta$ -lactamase extract.

**$\beta$ -Lactamase purification.** The  $\beta$ -lactamase extract from *E. coli* DH10B (pBS2) was filtered through a 0.45- $\mu$ m-pore-size filter (Millipore, Saint-Quentin-en-Yvelines, France) prior its loading onto a preequilibrated Q-Sepharose column (Amersham Pharmacia Biotech). The enzyme which was recovered in the flowthrough was then dialyzed overnight at 4°C against 50 mM phosphate buffer, pH 7. The enzymatic fraction was then loaded onto a preequilibrated S-Sepharose column (Amersham Pharmacia Biotech). The enzyme was eluted by a linear NaCl gradient (0 to 1 M) in phosphate buffer (pH 7). The  $\beta$ -lactamase was eluted at a concentration of 170 mM NaCl. The fraction containing the  $\beta$ -lactamase activity was dialyzed overnight against 30 mM cacodylate buffer, pH 6.5, containing 50  $\mu$ M ZnCl<sub>2</sub>. The specific activities of the  $\beta$ -lactamase extract and of the purified  $\beta$ -lactamase from *E. coli* DH10B (pBS2) were compared using 100  $\mu$ M of imipenem as substrate as previously described (40).

**N-terminal sequencing and isoelectric focusing.** In order to determine the site for cleavage of the mature protein of GOB-1  $\beta$ -lactamase, the purified enzyme was submitted to an Edman analysis (19) at the laboratory for protein microsequencing at the Pasteur Institute, Paris, France. Purified enzyme and marker proteins were subjected to sodium dodecyl sulfate-12.5% polyacrylamide gel electrophoresis (20 mA, 5 h, room temperature). Proteins were then electrotransferred onto a polyvinylidene difluoride membrane (Immobilon-P; Millipore) by using the Mini Protean II transfer cell (8 by 7.3 cm) (Bio-Rad) in 50 mM Tris-50 mM borate buffer (pH 8.7) at room temperature (3.5 V/cm, overnight). The membrane was then rinsed in distilled water and stained with a solution made of 0.05% Coomassie brilliant blue R-250 in methanol and water (50:50 [vol/vol]) for 5 min. The membrane was then destained in methanol and water (50:40 [vol/vol]) and acetate and water (10:40 [vol/vol]). The protein band was then excised with a razor blade and allowed to air dry. The amino-terminal sequence of the  $\beta$ -lactamase was determined with an automated Edman sequencer on a model 473A gas phase sequencer (Applied Biosystems).

The purified enzyme from a culture of *E. coli* DH10B (pBS2) and  $\beta$ -lactamase extracts from cultures of 10 *C. meningosepticum* isolates were subjected to analytical IEF on an ampholine polyacrylamide gel with a pH of 3.5 to 9.5 (Ampholine PAG plate; Amersham Pharmacia Biotech) for 90 min at 1,500 V, 50 mA, and 30 W. The focused  $\beta$ -lactamases were detected by overlaying the gel with 1 mM nitrocefin (Oxoid, Paris, France) or with an iodine-starch agar gel containing 0.5% (wt/vol) of imipenem (31) in 100 mM phosphate buffer (pH 7.0). These gels were preincubated with or without 100 mM EDTA (ethylenediaminetetraacetic acid) and with or without 5 mM clavulanic acid (38). The pI values were determined and compared to those of known  $\beta$ -lactamases.

**Kinetic measurements and relative molecular mass determination.** Purified  $\beta$ -lactamase was used for kinetic measurements performed at 30°C in 30 mM cacodylate (pH 6.5) supplemented with 50  $\mu$ M ZnCl<sub>2</sub> as described previously (46). The rates of hydrolysis were determined with a Pharmacia ULTROSPEC 2000 spectrophotometer and were computer analyzed using the SWIFT II software (Amersham Pharmacia Biotech).

$K_m$  and  $k_{cat}$  values were determined by analyzing the  $\beta$ -lactam hydrolysis under initial rate conditions by using the Eadie-Hoffstee linearization of the Michaelis-Menten equation as previously described (13, 41).

Various concentrations of EDTA or clavulanic acid were preincubated with the enzyme for 10 min at 30°C before testing the rate of imipenem hydrolysis. The 50% inhibitory concentration (IC<sub>50</sub>) of these inhibitors was then determined.

The relative molecular mass of the purified  $\beta$ -lactamase was determined by gel filtration using a 1.6- by 47-cm column packed with Superdex 75 (Amersham Pharmacia Biotech) equilibrated and eluted with phosphate buffer (pH 7) containing 150 mM NaCl. Each elution peak was tested for  $\beta$ -lactamase activity by using nitrocefin as substrate. The peak that showed the highest  $\beta$ -lactamase activity was linearly plotted against the logarithm of the molecular masses of the standard proteins (Amersham Pharmacia Biotech) to determine the relative molecular mass of the purified  $\beta$ -lactamase.

**Nucleotide sequence accession numbers.** The nucleotide and deduced  $\beta$ -lactamase amino acid sequences reported in this work have been assigned to the GenBank and EMBL databases under the accession no. AF189290 to AF189305 and AF090141. The nucleotide sequences of the 16S rDNAs have been assigned to the accession no. AF207070 to AF207079.

1  
3  
83  
163  
243  
1  
303  
21  
363  
41  
423  
61  
483  
81  
543  
101  
603  
121  
663  
141  
723  
161  
783  
181  
843  
201  
903  
221  
963  
241  
1023  
261  
1083  
281  
1151  
1231  
1311  
1391  
1471  
1551  
1631  
1711  
1791  
1871  
1951  
2031  
2111  
2191  
2251  
2331

GA

TCCTGCTTTTATTCTAATGAAAACCGAACCCCTTGAAGTGATTAACAAAATATGGGATTTCCGTAGAAATTACCGGATTAC  
CTCTATTCCTTACACTGGATGCAGGTGCTAATGTCCACCTGTTGTTCCCGAATGATATGAAAAGTGATAAAATAAAAAATA

-35

TTTATTCAGCAGGAGCTTTTACCTTTTACCACAAAAGGGGAGTGGTAAAAGATGAAATGTGCTTCTTAAACATATTGCT

-10

**ATG** AGA AAT TTT GCT ACA CTG TTT TTC ATG TTC ATT TGC TTG GGC TTG AAT GCT CAG GTA

primer1 → RBS

M R N F A T L F F M F I C L G L N A Q V

**bla<sub>GOB-1</sub>** → ↑

GTA AAA GAA CCT GAA AAT ATG CCC AAA GAA TGG AAC CAG GCT TAT GAA CCA TTC AGA ATT  
V K E P E N M P K E W N Q A Y E P F R I

GCA GGT AAT TTA TAT TAC GTA GGA ACC TAT GAT TTG GCT TCT TAC CTT ATT GTG ACA GAC  
A G N L Y Y V G T Y D L A S Y L I V T D

AAA GGC AAT ATT CTC ATT AAT ACA GGA ACG GCA GAA TCG CTT CCA ATA ATA AAA GCA AAT  
K G N I L I N T G T A E S L P I I K A N

ATC CAA AAG CTC GGG TTT AAT TAT AAA GAC ATT AAG ATC TTG CTG CTT ACT CAG GCT CAC  
I Q K L G F N Y K D I K I L L L T Q A H

TAC GAC CAT ACA GGT GCA TTA CAG GAT TTT AAA ACA GAA ACC GCT GCA AAA TTC TAT GCC  
Y D H T G A L Q D F K T E T A A K F Y A

GAT AAA GCA GAT GTT GAT GTC CTG AGA ACA GGG GGG AAG TCC GAT TAT GAA ATG GGA AAA  
D K A D V D V L R T G G K S D Y E M G K

TAT GGT GTG ACA TTT AAA CCT GTT ACT CCG GAT AAA ACA TTG AAA GAT CAG GAT AAA ATA  
Y G V T F K P V T P D K T L K D Q D K I

AAA CTG GGA AAT ATA ACC CTG ACT TTG CTT CAT CAT CCG GGA CAT ACA AAA GGT TCC TGT  
K L G N I T L T L L H H P G H T K G S C

AGT TTT ATT TTT GAA ACA AAA GAC GAG AAG AGA AAA TAT AGA GTT TTG ATA GCT AAT ATG  
S F I F E T K D E K R K Y R V L I A N M

CCC TCC GTT ATT GTT GAT AAG AAA TTT TCT GAA GTT ACC GCA TAT CCA AAT ATT CAG TCC  
P S V I V D K K F S E V T A Y P N I Q S

GAT TAT GCT TAT ACC TTT GGT GTT ATG AAA AAG CTG GAT TTT GAT ATT TGG GTG GCC TCC  
D Y A Y T F G V M K K L D F D I W V A S

CAT GCA AGT CAG TTC GAT CTC CAT GAA AAA CGT AAA GAA GGA GAT CCG TAC AAT CCG CAA  
H A S Q F D L H E K R K E G D P Y N P Q

TTG TTT ATG GAT AAG CAA AGC TAT TTC CAA AAC CTT AAT GAT TTG GAA AAA AGC TAT CTC  
L F M D K Q S Y F Q N L N D L E K S Y L

GAC AAA ATA AAA AAA GAT TCC CAA GAT AAA TAA GTATGAAAACAATTCCTTCTTCTCAGCATTAAT  
D K I K K D S Q D K \* primer 2

AAGCAGAAATTTGATTATACCGATGTTTATTTCCAGGAGGTGAAAACCTGAAAAAATATCTGCCCTGAAGATTTAGGAA  
AGGCTTTCTTTACACGCGACATTCCTTGGGTGAAAAACTTTTTACACTGCGCAATAAGCTGGTTCAGTATTCGGATTA  
AAAGGATCTGATAAGAAAAGTAAAATTTATCCAGCAGGAGCAATCGGATTTTGTCTGAGGTGAAAGGTTTGGATTGTT  
TAAAGTTCTGGATAAAAAAGAAAAGAAATTTCTGGGCGAAGATGATAAACATCTGGATTTTAAAGTATCCTTACTCT  
ATGCTCAACCAGAAAACAAAATTTATATTTCCACTGGTGTGCAGTATCATAATTTCTTTGGGAGGCTTTTACCTTTTCTT  
GTTAAACCTTTCCACAGATTTGGTTGTAAAGTCTATGTTGAACTCTATGGCAACAAGCTTTGCTTGATTTTAAATAACATCT  
ATAACTATCCTCCGCTACCAGATAAAAAAGGATGAAAAGAAGCTATAACGAAAAGGAGACTCTTACGTAATAAATTAAGATTT  
GGTTCATGAATCAGATCCCGGCAAAAGCAGTATTTAGGAAAACAATATTTCAATCTGGTTTATTTTGATTCTGGCTGT  
AATTTGTTGTACCTGCTGTAATAATGATGGAGAAGGATAACCAGAAAGTATGATTAAGTATAAAGCTTTTCAATGGCTGCTA  
TTTTTTGTTATTGGGCCCTTATAAAAATTGATTCITGGCTATATATTTCTGAAATGACATGAGTAATAAAGGTGAGAAA  
ATTTTCGGTAGAGAATTAATTTGCTGGAATGATCAAAAAGAAATTAACCTGTCGGACTGTATGCTGGAGATGCACGGCT  
AATTTATGTAAGAGAAATAATAAAGAATTTACGGAGGATTTTAAAAATCTTAATACAAATAGCTATAAGCTGGCATTGA  
TAGCTGTTCTTTTGTCTAAGAAAATATAAAAACAAGAGATATTTCTCTGCTATTAATAATATTAACAACCTGCTGAAGA  
CTTATAAGATGACACCAAAAACATCTCATCGTTTCAGACAGATTTTCTCATTTTTATATTAGACTTTGTATAGCTGT TTA\*

CCA GTC CTT AGA ATA AGG TGT ATT GGA ATA TAC CAG TTC ATC ACC GTA TAA TTC TTT TGC  
W D K S Y P T N S Y V L E D G Y L E K A

GAT AAG CTT AAG CGC AGG AAG CTG GCC AGA AGT GAA ATT ACT GCG GTT AGG ATC 2384  
I L K L A P L Q G S T F N S R N P D

← Endo-Beta-N-Acetylglucosaminidase gene

FIG. 1. Nucleotide sequence of a 2,384-bp DNA fragment of recombinant plasmid pBS2 carrying *bla<sub>GOB-1</sub>* and the 117 bp of the 3' end of the endo-beta-N-acetylglucosaminidase gene of *C. meningosepticum* PINT. The deduced amino acid sequences are given in a single-letter code. The start and stop codons of the *bla<sub>GOB-1</sub>* gene and the stop codon of the endo-beta-N-acetylglucosaminidase gene are in bold. The vertical arrow indicates the peptide leader cleavage site in *E. coli* as determined by N-terminal sequencing. The putative -35 and -10 sequences of the putative promoter and ribosome binding site (RBS) for *bla<sub>GOB-1</sub>* are underlined. Primers 1, 2, and 3 used to PCR amplify *bla<sub>GOB-1</sub>*-like genes from other *C. meningosepticum* isolates are indicated by an arrow.




FIG. 2. Multiple-sequence alignment of amino acid sequence of GOB-1 from *C. meningosepticum* PINT isolate with those of eight class B CHβLs. Sequence comparison was performed first by aligning the proteins by using the ClustalW program. Then, adjustments were made to reduce the number of gaps and to maintain alignment of the putative active residues of the active sites. The origins of metallo-β-lactamases are as follows: CphA-1 from *A. hydrophila* AE036 (31), BII from *B. cereus* 5/B/6 (29), BlaB (BlaB-1) from *C. meningosepticum* CIP 6058 (NCTC 10585) (46), IND-1 from *C. indologenes* (5), VIM-1 from *P. aeruginosa* VR-143/97 (28), CcrA from *B. fragilis* TAL 3636 (44), IMP-1 from *S. marcescens* TN9106 (36), and L-1 from *S. maltophilia* IID1275 (57). Amino acids that were identical for at least five out of nine aligned amino acid sequences are shaded in grey. Stars refer to conserved amino acids identified by crystal structure determination as interacting in the binding to the Zn<sup>2+</sup> cofactor or to the water molecule in the *B. cereus* 569H/9 enzyme or in CcrA (12, 20). The numbering scheme refers to the CcrA enzyme (44). Dashes indicate gaps introduced to optimize the alignment.

## RESULTS

**Cloning and sequence analysis of *bla*<sub>GOB-1</sub>.** Partially *Sau*3AI-digested genomic DNA from *C. meningosepticum* PINT was cloned into the *Bam*HI site of pBK-CMV. Three recombinant *E. coli* DH10B clones were obtained. One of them, harboring pBS2 (the smallest insert [2.4 kb]), was selected for further studies.

DNA sequence analysis of the 2,384-bp insert of pBS2 revealed an ORF of 873 bp, encoding a 290-amino-acid preprotein (Fig. 1). Putative  $-35$  (TTGAAA) and  $-10$  (TTTATT) promoter regions and a ribosome binding site (AAAACA) were found along with a putative ATG initiation codon at position 243 (Fig. 1).

The G+C content of this ORF was 36%, which lies close to the G+C ratio found for other *C. meningosepticum* genes recorded in the EMBL and GenBank sequence database (36.1 to 41.6%). The codon usage of this ORF was also similar to those calculated for the set of these *C. meningosepticum* genes (data not shown). From the sequencing data, one would expect the first 18 amino acids of this ORF, which contains numerous hydrophobic residues found by hydrophobicity analysis, to be the leader peptide (Fig. 1). This was indeed the case, since Edman analysis (nine cycles) determined the N-terminal sequence of the purified protein from a culture of *E. coli* DH10B (pBS2) cells as being QVVK. The cleavage site of the leader peptide was therefore deduced to be just after the alanine residue at position 18 (Fig. 1).

Further DNA sequence analysis of the downstream region of this ORF identified the 3' end terminal sequence of an endo-beta-*N*-acetylglucosaminidase F1 gene (Fig. 1) (54).

The mature protein (named GOB-1 for class B  $\beta$ -lactamase of *C. meningosepticum*) expressed in *E. coli* DH10B cells had a relative molecular mass determined by gel filtration to be 28.2 kDa. His-101, Asp-103, His-162, and His-225 identified by biochemical analysis or by crystal structure analysis as interacting with a Zn<sup>2+</sup> cofactor in *Bacillus cereus* 569H/9 enzyme or in CcrA were found in GOB-1 (Fig. 2) (10, 12). However, the histidine residue at position 99 found in most class B CH $\beta$ Ls was changed for a glutamine residue in GOB-1 (Fig. 2). The comparison of GOB-1 with other class B  $\beta$ -lactamases revealed only weak identity (Fig. 3). The highest percentage of identity was with L-1 from *Stenotrophomonas maltophilia* (18%) and only 11% with BlaB-1 from *C. meningosepticum*.

**$\beta$ -Lactam resistance phenotype and plasmid analysis.** The MICs of  $\beta$ -lactams for *C. meningosepticum* PINT showed that it was resistant to all tested  $\beta$ -lactams except piperacillin, as previously reported (Table 2) (6, 16). Similar MICs (within a two-dilution range) were obtained for the *C. meningosepticum* isolates except for *C. meningosepticum* H01J100, for which MICs of all  $\beta$ -lactams were lower (data not shown).

Recombinant plasmids pBS3 and pBS4 were constructed by cloning the ORF of *bla*<sub>GOB-1</sub> and *bla*<sub>BlaB-1</sub> in plasmid pPCR-Script Cam SK, respectively, without the putative promoter regions of these  $\beta$ -lactamase genes (Table 1). *E. coli* DH10B (pBS3) showed a decreased susceptibility to all  $\beta$ -lactams except to aztreonam (Table 2), thus indicating that *bla*<sub>GOB-1</sub> was involved at least partially in the resistance to carbapenems of *C. meningosepticum* PINT. MICs of penicillins were higher against *E. coli* DH10B (pBS4) than those against *E. coli* DH10B (pBS3), while the opposite was found for cephalosporins (Table 2). Both recombinant *E. coli* strains remained fully susceptible to aztreonam. MICs of carbapenems were similar against *E. coli* DH10B (pBS3) and *E. coli* DH10B (pBS4), although the amino acid identity of GOB-1 and BlaB-1 was low.




FIG. 3. Dendrogram obtained for nine representative CH $\beta$ Ls calculated with ClustalW followed by adjustments to reduce the number of gaps and to maintain alignment of the residues identified in the active sites of some CH $\beta$ Ls. Branch lengths are to scale and proportional to the number of amino acid changes. The percentages at the branching point (bold and underlined) refer to the number of times a particular node was found in 100 bootstrap replications (the stars indicate uncertainty of nodes with bootstrap values of less than 50%). The distance along the vertical axis has no significance. BlaB-1 (BlaB) and GOB-1 were from *C. meningosepticum*, IND-1 was from *C. indologenes*, CphA-1 was from *A. hydrophila*, L-1 was from *S. maltophilia*, BII was from *B. cereus*, VIM-1 and VIM-2 were from *P. aeruginosa*, CcrA was from *B. fragilis*, and IMP-1 was from *S. marcescens*. Percent amino acid identities to GOB-1 are indicated in parentheses.

Plasmid analysis and attempts to transfer the  $\beta$ -lactam resistance markers from *C. meningosepticum* to *E. coli* failed, thus suggesting the likely chromosomal origin of *bla*<sub>GOB-1</sub>.

**Biochemical properties of GOB-1.** IEF analysis revealed that *E. coli* DH10B (pBS2) produced only one  $\beta$ -lactamase activity with a pI value of 8.7. This pI value did not correspond to the pI value of 8.3 found for the carbapenem-hydrolyzing activity identified in *C. meningosepticum* PINT.

Specific activity prior to and after purification enabled us to determine the 400-fold purification factor for GOB-1 from *E. coli* DH10B (pBS2). The specific activity of the purified enzyme was 73.2  $\mu\text{mol} \cdot \text{min}^{-1} \cdot \text{mg}$  of protein<sup>-1</sup>.

Kinetic parameters of GOB-1 revealed a broad spectrum of hydrolysis with a strong activity against meropenem, compared to that against imipenem (Table 3). GOB-1  $\beta$ -lactamase has a strong activity against amoxicillin, benzylpenicillin, piperacillin, and extended-spectrum cephalosporins. Hydrolysis of aztreonam was not detectable. The hydrolytic activity of GOB-1  $\beta$ -lactamase was inhibited by EDTA (IC<sub>50</sub>, 25  $\mu\text{M}$ ) but not by class A  $\beta$ -lactamase inhibitors, such as clavulanic acid (IC<sub>50</sub>,

TABLE 3. Kinetic parameters of  $\beta$ -lactam antibiotics for the purified carbapenem-hydrolyzing  $\beta$ -lactamase GOB-1

Substrate	$K_m$ ( $\mu$ M)	$k_{cat}$ ( $s^{-1}$ )	$k_{cat}/K_m$ ( $\mu$ M $^{-1}$ s $^{-1}$ ) <sup>a</sup>
Benzylpenicillin	109	204	1.87
Amoxicillin	1,024	357	0.35
Ticarcillin	147	76.3	0.52
Piperacillin	169	279	1.66
Cephalothin	24	16.1	0.67
Cefepime	52.6	10.7	0.20
Cefoxitin	46.8	11.9	0.25
Cefuroxime	26.9	26.3	0.98
Ceftazidime	71.4	54.5	0.76
Cefotaxime	51.1	43.7	0.85
Aztreonam	ND <sup>b</sup>	<0.5	— <sup>c</sup>
Moxalactam	78.8	10.4	0.13
Imipenem	60	39.4	0.66
Meropenem	5.4	29.2	5.34

<sup>a</sup> Standard deviations were within 10%.

<sup>b</sup> ND, not determinable.

<sup>c</sup> —, the hydrolysis parameter could not be calculated.

>10 mM). GOB-1 was therefore classified the functional CH $\beta$ L group 3a according to the Bush classification (9, 43).

**Distribution of GOB-1-like and BlaB-like  $\beta$ -lactamases and 16S rDNA sequencing.** EDTA-inhibited activities obtained by comparison of pI values with or without EDTA were heterogeneous for the 10 *C. meningosepticum* isolates (Table 4). Only one EDTA-inhibited hydrolysis activity was detected for *C. meningosepticum* PINT, AMA, 7830, 79.5, CIP 6057, AB1572, and H01J100 isolates. Three isolates produced two EDTA-inhibited activities (Table 4). Additionally, clavulanic acid-inhibited  $\beta$ -lactamase activities varied from one isolate to the other (Table 4). Southern hybridization experiments using nonrestricted genomic DNA of *C. meningosepticum* isolates and a PCR-amplified 731-bp fragment internal to *bla*<sub>GOB-1</sub> as a probe yielded a hybridization signal that corresponded to the chromosomal band (data not shown), showing that each *C. meningosepticum* isolate possessed a chromosomally located *bla*<sub>GOB-1</sub>-like gene. PCR fragments of GOB-1- and BlaB-1-like genes of 10 *C. meningosepticum* isolates (except for a *bla*<sub>GOB-1</sub>-like gene from *C. meningosepticum* CIP 7830 that failed to yield a PCR-positive result) were sequenced on both strands. Sequences for entire *bla*<sub>BlaB-1</sub>-like genes and a partial portion of the *bla*<sub>GOB-1</sub>-like genes yielding 252 out of 290 amino acids were obtained using the designed PCR primers. The deduced amino acid sequences revealing heterogeneity among GOB-1-like  $\beta$ -lactamases having 90 to 100% amino acid identity (Fig. 4).

Alignment of the BlaB-1-like sequences of 10 *C. meningosepticum* isolates also revealed heterogeneity, with 86 to 100% amino acid identity (Fig. 5). The same GOB-1-like or BlaB-1-like sequences were found in several isolates, for example, GOB-1 in *C. meningosepticum* PINT, AB1572, and CIP 6057 and BlaB-1 in *C. meningosepticum* PINT and CIP 6058 (Table 4). However, within two given *C. meningosepticum* isolates, the same combination of GOB-1-like and BlaB-1-like  $\beta$ -lactamases was not found (Table 4). 16S rDNA sequencing identified homogeneous sequences (from 96 to 99% identity) among the studied *C. meningosepticum* isolates (data not shown, accession numbers available).

## DISCUSSION

GOB-1 is a broad-spectrum class B  $\beta$ -lactamase like the previously identified BlaB-1 (BlaB) in *C. meningosepticum* NCTC 10585 (CIP 6058). Comparison of their kinetic constants revealed that BlaB-1 hydrolyzed benzylpenicillin better

TABLE 2. MICs of  $\beta$ -lactams for *C. meningosepticum* PINT, *E. coli* DH10B (pBS3), *E. coli* DH10B (pBS4), and the *E. coli* DH10B reference strain

$\beta$ -Lactam	MIC ( $\mu$ g/ml)			
	<i>C. meningosepticum</i> PINT	<i>E. coli</i> DH10B (pBS3) <sup>a</sup>	<i>E. coli</i> DH10B (pBS4) <sup>b</sup>	<i>E. coli</i> DH10B
Amoxicillin	256	64	128	4
Ticarcillin	256	64	256	4
Piperacillin	32	2	4	1
Cephalothin	512	32	16	2
Cefepime	32	0.06	0.03	0.03
Cefoxitin	32	16	2	1
Cefpirome	32	0.5	0.06	0.06
Ceftazidime	256	16	0.5	0.5
Cefotaxime	64	0.25	0.12	0.12
Aztreonam	>512	0.25	0.25	0.25
Moxalactam	64	1	0.12	0.12
Imipenem	32	0.5	0.5	0.12
Meropenem	16	0.12	0.12	0.06

<sup>a</sup> *E. coli* DH10B (pBS3) expressed GOB-1.

<sup>b</sup> *E. coli* DH10B (pBS4) expressed BlaB-1.

than GOB-1. Additionally, a comparison of MICs of  $\beta$ -lactams for *E. coli* expressing either GOB-1 or BlaB-1 revealed that GOB-1 hydrolyzed ceftazidime and cefoxitin more significantly than BlaB-1 does (hydrolysis constants of BlaB-1 for ceftazidime are not available [46]). GOB-1  $\beta$ -lactamase hydrolysis of meropenem was greater than that of imipenem. Imipenem is usually hydrolyzed better than meropenem by class B CH $\beta$ Ls with two exceptions, the group 3a *B. cereus* II enzyme and the group 3b AsbM1 enzyme from *A. hydrophila* (43). GOB-1, like BlaB-1, conferred only a slight increase in the MICs of carbapenems once its gene was cloned on a multicopy plasmid and expressed in *E. coli*. Similar results have been found for the CH $\beta$ Ls IMP-1, VIM-1, and VIM-2 (28, 36, 42). These results, together with data for kinetic constants of carbapenems, may indicate that an additional decrease of outer membrane permeability for carbapenems may explain the resistance to carbapenems observed for *C. meningosepticum* (32). In this regard, the pI value of 8.3 for the EDTA-inhibited  $\beta$ -lactamase identified in *C. meningosepticum* PINT did not correspond to the pI value of 8.7 for GOB-1 expressed in *E. coli* DH10B. This result may be explained either by a pI value of 8.3 corresponding to BlaB-1 also found in *C. meningosepticum* PINT, by a weak or lack of expression of GOB-1, or to differences in leader peptide cleavage in *E. coli* and in *C. meningosepticum*. Such a difference in the N-terminal end of the mature protein of GOB-1 may lead to its low concentration in the periplasmic space in *E. coli*. Whatever the reason is, the low level of resistance to carbapenems conferred by GOB-1 in *E. coli* may explain its difficulty in being detected once expressed in enterobacterial clinical isolates. Studies of the pI values of the *C. meningosepticum* isolates revealed that GOB-1-like and BlaB-1-like  $\beta$ -lactamases may not always be expressed since for some *C. meningosepticum* isolates, only one EDTA-inhibited  $\beta$ -lactamase was evidenced by IEF gel electrophoresis although two CH $\beta$ L genes had been identified (Table 4). However, since the pI values of GOB-1 and BlaB-1 were very close, one cannot exclude that they cannot be distinguished on the IEF gel.

Several variants of CH $\beta$ Ls have been found in *S. maltophilia*, *A. hydrophila*, and *Bacteroides fragilis*. However, in these species, it was determined that variants from reference CH $\beta$ Ls had 88 to 95% identity (31, 38, 43, 47, 48). To the best of our knowledge, it is the first time that two CH $\beta$ Ls with only 11%

TABLE 4. pI values of β-lactamase activity detected in *C. meningosepticum* isolates and in *E. coli* DH10B harboring pBS2 (GOB-1) or pBS4 (BlaB-1) and the corresponding GOB-1-like and BlaB-1-like sequences

Strains	pI values		Shared amino acid sequence	
	Clavulanic acid-inhibited β-lactamase activity	EDTA-inhibited β-lactamase activity	GOB-1 like	BlaB-1 like
<i>C. meningosepticum</i> PINT	7.6	8.3	GOB-1	BlaB-1
<i>C. meningosepticum</i> CIP 6058	8.5	7.8, 8.7	GOB-5	BlaB-1
<i>C. meningosepticum</i> AMA	8.5	8.3	GOB-6	BlaB-2
<i>C. meningosepticum</i> GEO	7.0	7.5, 8.5	GOB-4	BlaB-3
<i>C. meningosepticum</i> CIP 7830	7.5	8	+ <sup>a</sup>	BlaB-6
<i>C. meningosepticum</i> CIP 6059	8.4	7.5, 8.5	GOB-3	BlaB-3
<i>C. meningosepticum</i> CIP 79.5	7.6	8.4	GOB-7	BlaB-5
<i>C. meningosepticum</i> AB1572	7.6	8.3	GOB-1	BlaB-7
<i>C. meningosepticum</i> H01J100	8.1	8.3	GOB-2	BlaB-8
<i>C. meningosepticum</i> CIP 6057	7.6	8.6	GOB-1	BlaB-4
<i>E. coli</i> DH10B (pBS2)	— <sup>b</sup>	8.7	GOB-1	—
<i>E. coli</i> DH10B (pBS4)	—	8.5	—	BlaB-1

<sup>a</sup> +, GOB-1-like positive results by hybridization but negative by PCR amplification.  
<sup>b</sup> —, not detectable.

amino acid identity were identified in the same bacterial species. The significance of this result remains to be determined. The regulation of these CHβLs, if any, would be of interest as described for the *A. hydrophila* CHβL (1). It may be hypothesized that CHβLs in *C. meningosepticum* may counteract the effect of antibiotics produced by this *Chryseobacterium* species (33, 37). Additionally, the presence of two CHβL genes in *C. meningosepticum* may be used as a tool for a PCR-based identification of this species.

The amino acid sequence of GOB-1 allowed its classification in the sequence-based subclass B3 of metallo-CHβLs (43) along with L-1, the only other member of this subgroup, whereas BlaB-1 is a member of the subclass B1.

The primary structure of GOB-1 β-lactamase keeps most of the conserved amino acid residues of class B β-lactamases that

act in the interaction with the Zn<sup>2+</sup> cofactor or with the water molecule located in the active site, as shown for CcrA (58) or for L-1 (55): His-101, Asp-103, His-162, and His-225 (43). However, like CphA-1, GOB-1 lacks the His-99 residue, which is also involved in Zn<sup>2+</sup> binding, but possesses instead a glutamine residue (asparagine in CphA) (31). Therefore, the absence of His-99 does not seem to be involved in narrowing the spectrum of GOB-1 (Fig. 2).

GOB-1 β-lactamase, like L-1, lacks a cysteine residue at position 181 that is involved in the interaction with a Zn<sup>2+</sup> ion. In L-1, Cys-181 function is replaced by a histidine residue located at position 104 (55). It could be the same for GOB-1, which possesses also a histidine residue at this same position.

While this work was in progress, two BlaB variants were reported in GenBank, BlaC from *C. meningosepticum* NCTC




FIG. 4. Amino acid comparison of the GOB-1-like β-lactamases from nine *C. meningosepticum* isolates. Dashes indicate identical amino acids, and dots indicate undetermined sequences. GOB-1 was from *C. meningosepticum* PINT, CIP 6057, and AB1572, GOB-2 was from *C. meningosepticum* H01J100, GOB-3 was from *C. meningosepticum* CIP 6059, GOB-4 was from *C. meningosepticum* GEO, GOB-5 was from *C. meningosepticum* CIP 6058, GOB-6 was from *C. meningosepticum* AMA, and GOB-7 was from *C. meningosepticum* CIP 79.5. Numbering is according to the GOB-1 sequence.




FIG. 5. Amino acid comparison of the BlaB-1-like β-lactamases from 10 *C. meningosepticum* isolates. Dashes indicate identical amino acids. BlaB-1 was from *C. meningosepticum* CIP 6058 and PINT, BlaB-2 was from *C. meningosepticum* AMA, BlaB-3 was from *C. meningosepticum* GEO and CIP 6059, BlaB-4 was from *C. meningosepticum* CIP 6057, BlaB-5 was from *C. meningosepticum* CIP 79.5, BlaB-6 was from *C. meningosepticum* CIP 7830, BlaB-7 was from *C. meningosepticum* AB1572, and BlaB-8 was from *C. meningosepticum* H01J100. Numbering is according to the BlaB-1 sequence.

10016 and BlaB-2 from *C. meningosepticum* 97/P/5443. We have also identified BlaC (BlaB-4) from the same *C. meningosepticum* NCTC 10016 isolate and BlaB-2 from another *C. meningosepticum* isolate (*C. meningosepticum* AMA).

Although some genetic variation was identified among BlaB-1-like and GOB-1-like sequences, none of the studied *C. meningosepticum* isolates could be assigned to a special *C. meningosepticum* subgroup. Indeed, the *C. meningosepticum* isolates had 96 to 99% identity, according to the results of 16S rDNA sequencing.

Time will tell if gram-negative aerobes, such as *C. meningosepticum*, may be a reservoir for diffusion of CHβL genes to opportunistic pathogens. *P. aeruginosa* and *Acinetobacter* spp. that share low natural permeability towards most β-lactams are good candidates for expressing these carbapenem resistance genes. Finally, since *C. meningosepticum* CHβLs provide only a low level of resistance to carbapenems once they are expressed in *E. coli*, their routine detection in gram-negative clinical pathogens shall be performed at best with PCR-based methods previously described for *bla*<sub>IMP-1</sub> detection among American and Japanese isolates (23, 52).

ACKNOWLEDGMENTS

This work was funded by a grant from the Ministère de l'Éducation Nationale et de la Recherche, Université Paris XI, Faculté de Médecine Paris Sud (grant UPRES, JE-2227), and the French network "Les β-lactamases: de l'observation clinique à la structure," France.

We thank E. Ronco and B. Bruun for the gift of some *C. meningosepticum* isolates and L. Poirel for precious advice.

REFERENCES

1. Alksne, L. E., and B. A. Rasmussen. 1997. Expression of the AsbA1, OXA-12, and AsbM1 beta-lactamases in *Aeromonas jandaei* AER 14 is coordinated by a two-component regulon. *J. Bacteriol.* **179**:2006-2013.
2. Ambler, R. P. 1980. The structure of beta-lactamases. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* **289**:321-331.
3. Arakawa, Y., M. Murakami, K. Suzuki, H. Ito, R. Wacharotayankun, S. Oshuka, N. Kato, and M. Ohta. 1995. A novel integron-like element carrying the metallo-β-lactamase gene *bla*<sub>IMP</sub>. *Antimicrob. Agents Chemother.* **39**:1612-1615.
4. Avidor, B., Y. Kletter, S. Abulafia, Y. Golan, M. Ephros, and M. Giladi. 1997. Molecular diagnosis of cat scratch disease: a two-step approach. *J. Clin. Microbiol.* **35**:1924-1930.
5. Bellais, S., S. Léotard, L. Poirel, T. Naas, and P. Nordmann. 1999. Molecular characterization of a carbapenem-hydrolyzing β-lactamase from *Chryseobacterium (Flavobacterium) indologenes*. *FEMS Microbiol. Lett.* **171**:127-132.
6. Bellais, S., L. Poirel, T. Naas, D. Girlich, and P. Nordmann. 2000. Genetic-biochemical analysis and distribution of the Ambler class A β-lactamase CME-2, responsible for extended-spectrum cephalosporin resistance in *Chryseobacterium (Flavobacterium) meningosepticum*. *Antimicrob. Agents Chemother.* **44**:1-9.
7. Bloch, K. C., R. Nadarajah, and R. Jacobs. 1997. *Chryseobacterium meningosepticum*: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. *Medicine (Baltimore)* **76**:30-41.
8. Bush, K. 1998. Metallo-beta-lactamases: a class apart. *Clin. Infect. Dis.* **27**(Suppl. 1):S48-S53.
9. Bush, K., and G. A. Jacoby. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob. Agents Chemother.* **39**:1211-1233.
10. Carfi, A., S. Pares, E. Duee, M. Galleni, C. Duee, J.-M. Frère, and O. Dideberg. 1995. The 3-D structure of a zinc metallo-beta-lactamase from *Bacillus cereus* reveals a new type of protein fold. *EMBO J.* **14**:4914-4921.
11. Colding, H., J. Bangsborg, N. E. Fiehn, T. Bennekov, and B. Bruun. 1994. Ribotyping for differentiating *Flavobacterium meningosepticum* isolates from clinical and environmental sources. *J. Clin. Microbiol.* **32**:501-505.
12. Concha, N. O., B. A. Rasmussen, K. Bush, and O. Herzberg. 1996. Crystal structure of the wide-spectrum binuclear zinc metallo-β-lactamase from *Bacteroides fragilis*. *Structure* **4**:823-836.
13. Cornish-Bowden, A. 1995. Graphs of the Michaelis-Menten equation, p. 30-37. *In* Fundamentals of enzyme kinetics. Portland Press, Inc., Seattle, Wash.
14. Da Silva, G. J., and R. Leitão. 1999. Emergence of carbapenem-hydrolyzing enzymes in *Acinetobacter baumannii* clinical isolates. *J. Clin. Microbiol.* **37**:2109-2110.
15. Felici, A., G. Amicosante, A. Oratore, R. Strom, P. Ledent, B. Joris, L. Fanuel, and J. M. Frère. 1993. An overview of the kinetic parameters of class B β-lactamases. *Biochem. J.* **291**:151-155.
16. Fraser, S. L., and J. H. Jorgensen. 1997. Reappraisal of the antimicrobial susceptibilities of *Chryseobacterium* and *Flavobacterium* species and methods for reliable susceptibility testing. *Antimicrob. Agents Chemother.* **41**:2738-2741.



17. George, R., C. Cochran, and W. Wheeler. 1961. Epidemic meningitis of the newborn caused by *Flavobacterium*. Am. J. Dis. Child. **101**:296–304.
18. Hansen, J. B., and R. H. Olsen. 1978. Isolation of large bacterial plasmids and characterization of the P2 incompatibility group plasmids pMG1 and pMG5. J. Bacteriol. **135**:227–238.
19. Hewick, R. M., M. W. Hunkapiller, D. Le Hoo, and W. J. Dreyer. 1981. A gas-liquid solid phase peptide and protein sequenator. J. Biol. Chem. **256**:7990–7997.
20. Hussain, M., A. Carlino, M. J. Madonna, and J. O. Lampen. 1985. Cloning and sequencing of the metalloprotein  $\beta$ -lactamase II gene of *Bacillus cereus* 569/H in *Escherichia coli*. J. Bacteriol. **164**:223–229.
21. Ito, H., Y. Arakawa, S. Ohsuka, R. Wacharotayankun, N. Kato, and M. Ohta. 1995. Plasmid-mediated dissemination of the metallo- $\beta$ -lactamase gene *bla*<sub>IMP</sub> among clinically isolated strains of *Serratia marcescens*. Antimicrob. Agents Chemother. **39**:824–829.
22. Iyobe, S., H. Yamada, and S. Minami. 1996. Insertion of a carbapenemase gene cassette into an integron of a *Pseudomonas aeruginosa* plasmid. J. Antimicrob. Chemother. **38**:1114–1115.
23. Jones, R. N., M. A. Pfaller, S. A. Marshall, R. J. Hollis, and W. W. Wilke. 1997. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diagn. Microbiol. Infect. Dis. **29**:187–192.
24. Kado, C. I., and S. T. Liu. 1981. Rapid procedure for detection and isolation of large and small plasmids. J. Bacteriol. **145**:1365–1373.
25. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. **157**:105–132.
26. Laraki, N., M. Galleni, I. Thamm, M. L. Riccio, G. Amicosante, J.-M. Frère, and G. M. Rossolini. 1999. Structure of In31, a *bla*<sub>IMP</sub>-containing *Pseudomonas aeruginosa* integron phylogenetically related to In5, which carries an unusual array of gene cassettes. Antimicrob. Agents Chemother. **43**:890–901.
27. Laraki, N., N. Franceschini, G. M. Rossolini, P. Santucci, C. Meunier, E. de Pauw, G. Amicosante, J.-M. Frère, and M. Galleni. 1999. Biochemical characterization of the *Pseudomonas aeruginosa* 101/477 metallo- $\beta$ -lactamase IMP-1 produced by *Escherichia coli*. Antimicrob. Agents Chemother. **43**:902–906.
28. Lauretti, L., M. L. Riccio, A. Mazzariol, G. Cornaglia, G. Amicosante, R. Fontana, and G. M. Rossolini. 1999. Cloning and characterization of *bla*<sub>VIM</sub>, a new integron-borne metallo- $\beta$ -lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. Antimicrob. Agents Chemother. **43**:1584–1590.
29. Lim, H. M., J. J. Pene, and R. Shaw. 1988. Cloning, nucleotide sequence, and expression of the *Bacillus cereus* 5/B/6  $\beta$ -lactamase II structural gene. J. Bacteriol. **170**:2873–2878.
30. Livermore, D. M. 1997. Acquired carbapenemases. J. Antimicrob. Chemother. **39**:673–676.
31. Massidda, O., G. M. Rossolini, and G. Satta. 1991. The *Aeromonas hydrophila cphA* gene: molecular heterogeneity among metallo- $\beta$ -lactamases. J. Bacteriol. **173**:4611–4617.
32. Matsumura, N., S. Minami, Y. Watanabe, S. Iyobe, and S. Mitsuhashi. 1999. Role of permeability in the activities of  $\beta$ -lactams against gram-negative bacteria which produce a group 3  $\beta$ -lactamase. Antimicrob. Agents Chemother. **43**:2084–2086.
33. Medeiros, A. A. 1997. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin. Infect. Dis. **24** (Suppl. 1):S19–S45.
34. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
35. Nordmann, P., and T. Naas. 1994. Sequence analysis of PER-1 extended-spectrum beta-lactamase from *Pseudomonas aeruginosa* and comparison with class A beta-lactamases. Antimicrob. Agents Chemother. **38**:104–114.
36. Osano, E., Y. Arakawa, R. Wacharotayankun, M. Ohta, T. Horii, H. Ito, F. Yoshimura, and N. Kato. 1994. Molecular characterization of an enterobacterial metallo  $\beta$ -lactamase found in a clinical isolate of *Serratia marcescens* that shows imipenem resistance. Antimicrob. Agents Chemother. **38**:71–78.
37. Palissa, H., H. von Dohren, H. Kleinkauf, H. H. Ting, and J. E. Baldwin. 1989. Beta-lactam biosynthesis in a gram-negative eubacterium: purification and characterization of isopenicillin N synthase from *Flavobacterium* sp. strain SC 12.154. J. Bacteriol. **171**:5720–5728.
38. Payne, D. J., R. Cramp, J. H. Bateson, J. Neale, and D. Knowles. 1994. Rapid identification of metallo- and serine beta-lactamases. Antimicrob. Agents Chemother. **38**:991–996.
39. Pickett, M. J. 1989. Methods for identification of flavobacteria. J. Clin. Microbiol. **27**:2309–2315.
40. Poirel, L., M. Guibert, D. Girlich, T. Naas, and P. Nordmann. 1999. Cloning, sequence analyses, expression and distribution of *ampC-ampR* from *Morganella morganii* clinical isolates. Antimicrob. Agents Chemother. **43**:769–776.
41. Poirel, L., T. Naas, M. Guibert, E. B. Chaibi, R. Labia, and P. Nordmann. 1999. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum  $\beta$ -lactamase encoded by an *Escherichia coli* integron gene. Antimicrob. Agents Chemother. **43**:573–581.
42. Poirel, L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J.-D. Cavallo, and P. Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid and integron-borne gene from a *Pseudomonas aeruginosa* clinical isolate in France. Antimicrob. Agents Chemother. **44**:891–897.
43. Rasmussen, B. A., and K. Bush. 1997. Carbapenem-hydrolyzing  $\beta$ -lactamases. Antimicrob. Agents Chemother. **41**:223–232.
44. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. 1990. Cloning and sequencing of the class B  $\beta$ -lactamase gene (*ccrA*) from *Bacteroides fragilis* TAL3636. Antimicrob. Agents Chemother. **34**:1590–1592.
45. Rossolini, G. M., N. Franceschini, L. Lauretti, B. Caravelli, M. L. Riccio, M. Galleni, J.-M. Frère, and G. Amicosante. 1999. Cloning of *Chryseobacterium (Flavobacterium) meningosepticum* chromosomal gene (*bla*<sub>A<sub>CME</sub></sub>) encoding an extended-spectrum class A  $\beta$ -lactamase related to the *Bacteroides* cephalosporinases and the VEB-1 and PER  $\beta$ -lactamases. Antimicrob. Agents Chemother. **43**:2193–2199.
46. Rossolini, G. M., N. Franceschini, M. L. Riccio, P. S. Mercuri, M. Perilli, M. Galleni, J.-M. Frère, and G. Amicosante. 1998. Characterization and sequence of the *Chryseobacterium (Flavobacterium) meningosepticum* carbapenemase: a new molecular class B  $\beta$ -lactamase showing a broad substrate profile. Biochem. J. **332**:145–152.
47. Saino, Y., F. Kobayashi, M. Inoue, and S. Mitsuhashi. 1982. Purification and properties of inducible penicillin  $\beta$ -lactamase isolated from *Pseudomonas maltophilia*. Antimicrob. Agents Chemother. **22**:564–570.
48. Sanschagrin, F., J. Duffresne, and R. C. Levesque. 1998. Molecular heterogeneity of the L-1 metallo- $\beta$ -lactamase family from *Stenotrophomonas maltophilia*. Antimicrob. Agents Chemother. **42**:1245–1248.
49. Segatore, B., O. Massidda, G. Satta, D. Setacci, and G. Amicosante. 1993. High specificity of *cphA*-encoded metallo-beta-lactamase from *Aeromonas hydrophila* AE036 for carbapenems and its contribution to beta-lactam resistance. Antimicrob. Agents Chemother. **37**:1324–1328.
50. Senda, K., Y. Arakawa, S. Ichiyama, K. Nakashima, H. Ito, S. Ohsuka, K. Shimokata, N. Kato, and M. Ohta. 1996. PCR detection of metallo- $\beta$ -lactamase gene (*bla*<sub>IMP</sub>) in gram-negative rods resistant to broad-spectrum  $\beta$ -lactams. J. Clin. Microbiol. **34**:2909–2913.
51. Senda, K., Y. Arakawa, K. Nakashima, H. Ito, S. Ichiyama, K. Shimokata, N. Kato, and M. Ohta. 1996. Multifocal outbreaks of metallo- $\beta$ -lactamase-producing *Pseudomonas aeruginosa* resistant to broad-spectrum  $\beta$ -lactams, including carbapenems. Antimicrob. Agents Chemother. **40**:349–353.
52. Siegman-Igra, Y., D. Schwartz, G. Soferman, and N. Konforti. 1987. *Flavobacterium* group IIb bacteremia: report of a case and review of *Flavobacterium* infections. Med. Microbiol. Immunol. **176**:103–111.
53. Swofford, D. L. 1989. PAUP (version 3.0): phylogenetic analysis using parsimony. Illinois Natural History Survey, Champaign, Ill.
54. Tarentino, A. L., G. Quinones, W. P. Schrader, L. M. Changchien, and T. H. Plummer, Jr. 1992. Multiple endoglycosidase (Endo) F activities expressed by *Flavobacterium meningosepticum*. Endo F1: molecular cloning, primary sequence, and structural relationship to Endo H. J. Biol. Chem. **267**:3868–3872.
55. Ullah, J. H., T. R. Walsh, I. A. Taylor, D. C. Emery, C. S. Verma, S. J. Gamblin, and J. Spencer. 1998. The crystal structure of the L1 metallo- $\beta$ -lactamase from *Stenotrophomonas maltophilia* at 1.7 Å resolution. J. Mol. Biol. **284**:125–136.
56. Vandamme, P., J. F. Bernardet, P. Segers, K. Kersters, and B. Holmes. 1994. New perspectives in the classification of the flavobacteria: description of *Chryseobacterium* gen. nov., *Bergeyella* gen. nov., and *Empedobacter* nom. rev. Int. J. Syst. Bacteriol. **44**:827–831.
57. Walsh, T. R., L. Hall, S. J. Assinder, W. W. Nichols, S. J. Cartwright, A. P. MacGowan, and P. M. Bennett. 1994. Sequence analysis of the L-1 metallo  $\beta$ -lactamase from *Xanthomonas maltophilia*. Biochim. Biophys. Acta **1218**:199–201.
58. Wang, Z., W. Fast, and S. J. Benkovic. 1999. On the mechanism of the metallo- $\beta$ -lactamase from *Bacteroides fragilis*. Biochemistry **38**:10013–10023.